Toshiki Etani, Shuhei Kondo, Ryohei Azuma, Rika Banno, Teruki Isobe, Nobuhiko Shimizu, Keitaro Iida, Tatsuya Hattori, Takashi Nagai, Taiki Kato, et al. Multicenter surveillance of the outcomes of and antimicrobial susceptibility to acute cystitis caused by Staphylococcussaprophyticus. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2024
Toshiki Etani, Chiharu Wachino, Takuya Sakata, Maria Aoki, Masakazu Gonda, Nobuhiko Shimizu, Takashi Nagai, Rei Unno, Kazumi Taguchi, Taku Naiki, et al. Using fosfomycin to prevent infection following ureterorenoscopy in response to shortage of cephalosporins: a retrospective preliminary study. BMC urology. 2024. 24. 1. 145-145
Teruki Isobe, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Keitaro Iida, Yusuke Noda, Nobuhiko Shimizu, Maria Aoki, et al. Experience and prognostic analysis with avelumab switch maintenance treatment in metastatic urothelial carcinoma. Oncology. 2024. 1-11
Shuzo Hamamoto, Yoshihiko Tasaki, Toshiharu Morikawa, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Rei Unno, Tomoki Takeda, Takashi Nagai, et al. Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma. Journal of Clinical Medicine. 2024. 13. 12. 3365-3365
Yoshihiko Tasaki, Shuzo Hamamoto, Taku Naiki, Toshiki Etani, Shoichiro Iwatsuki, Rei Unno, Takashi Nagai, Yoshihisa Mimura, Yosuke Sugiyama, Yuji Hotta, et al. MP10-06 ELEVATED EOSINOPHILS BEFORE 2 COURSE TREATMENT MAY BE A UNIVERSAL BIOMARKER FOR IMMUNE-RELATED ADVERSE EVENTS INDUCED BY COMMON TO DIFFERENT IMMUNE CHECKPOINT INHIBITOR AND CANCER TYPES INCLUDING TO UROLOGICAL CANCER. Journal of Urology. 2024. 211. 5S